17:20 EST Maze Therapeutics (MAZE) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics Secures New $200 Million Loan Facility
- Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
- Maze Therapeutics price target raised to $46 from $37 at BTIG
- Maze Therapeutics price target raised to $46 from $34 at Guggenheim